Both normal and transformed prostate epithelial cells have been shown to augment RAS/MAPK signaling in response to mTORC1 inhibition [235,255], and administration of Everolimus (RAD001) has been shown to induce MAPK signaling in a Pten-deleted mouse model of prostate cancer [235,255]. This evidence concerns the gene PTEN and prostate cancer.